Press releases
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
- Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
- Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
- Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
- Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
- Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
- Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
More ▼
Key statistics
As of last trade Ligand Pharmaceuticals Inc (LGDN:DUS) traded at 72.50, -13.17% below its 52-week high of 83.50, set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 73.50 |
---|---|
High | 73.50 |
Low | 72.50 |
Bid | 70.50 |
Offer | 72.00 |
Previous close | 74.50 |
Average volume | 0.00 |
---|---|
Shares outstanding | 17.71m |
Free float | 16.66m |
P/E (TTM) | 27.13 |
Market cap | 1.40bn USD |
EPS (TTM) | 2.91 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 15:31 BST.
More ▼